Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.86 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.62 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.48 |
| ▸ | NT5E | P21589 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23211669 | 1.00 | POLB (0.86) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL15146153 | 0.93 | POLB (1.00) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL9602217 | 0.91 | POLB (0.72) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL6100124 | 0.91 | POLB (0.79) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL16289468 | 0.91 | POLB (0.79) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL6206103 | 0.90 | POLB (0.78) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL9756890 | 0.89 | POLB (0.67) | POLBABL1RIN1RNASE1NT5E | |
| SCHEMBL9702839 | 0.87 | POLB (0.76) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL8003052 | 0.87 | POLB (0.76) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL14429248 | 0.86 | POLB (0.65) | POLBABL1RIN1RNASE1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | EVONETIX LTD. (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | SILICON VALLEY BANK | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | CTDSP1, RNGTT, SSU72 | POLB 24/4885ABL1 4312/4885RIN1 4631/4885 |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | CTDSP1, RNGTT, SSU72 | POLB 24/4885ABL1 4312/4885RIN1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.